• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

RCT Results: Does Remdesivir Prevent COVID-19 Progression in Outpatients?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Remdesivir has been shown to improve outcomes in hospitalized patients with moderate-to-severe COVID-19  
  • Gottlieb et al. (NEJM, 2021) evaluated the efficacy and safety of a 3-day course of remdesivir in high-risk, non-hospitalized patients with Covid-19 

METHODS: 

  • Randomized, double-blind, placebo-controlled trial 
    • PINETREE Clinical Trial  
  • Participants 
    • Non-hospitalized COVID-19 patients  
    • Symptom onset within the previous 7 days  
    • ≥1 risk factor for disease progression  
      • Age ≥60 years | Obesity | Coexisting medical conditions 
  • Interventions 
    • Intravenous remdesivir for 3 days 
      • 200 mg on day 1 and 100 mg on days 2 and 3 
    • Placebo 
  • Primary outcome 
    • A composite of COVID-19–related hospitalization or death from any cause by day 28 
  • Primary safety outcome 
    • Any adverse event 
  • Secondary outcome 
    • A composite of a COVID-19–related medically attended visit or death from any cause by day 28 

RESULTS: 

  • Remdesivir group: 279 patients | Placebo group: 283 patients 
    • Mean age: 50 years 
    • 47.9% women 
    • 41.8% Hispanic or Latino/a 
  • Common coexisting conditions 
    • Diabetes mellitus: 61.6% 
    • Obesity: 55.2% 
    • Hypertension: 47.7% 
  • Covid-19–related hospitalization or death from any cause was less frequent in the remdesivir group 
    • Remdesivir: 0.7% (2 patients) 
    • Placebo: 5.3% (15 patients) 
    • Hazard ratio (HR) 0.13 (95% CI, 0.03 to 0.59); P=0.008 
  • Patients in the remdesivir group were less likely to need medical treatment by day 28 
    • Remdesivir: 1.6% 
    • Placebo: 8.3% 
    • HR 0.19 (95% CI, 0.07 to 0.56) 
  • No patients had died by day 28 

Adverse Events 

  • Overall 
    • Remdesivir: 42.3%  
    • Placebo: 46.3%  
  • Most common in ≥5% in both groups  
    • Nausea | Headache | Cough 
  • Adverse events related to the trial regimen  
    • Remdesivir: 12.2% 
    • Placebo group: 8.8% 
  • Overall, fewer patients in the remdesivir group had serious adverse events 
    • Remdesivir: 1.8% 
    • Placebo: 6.7%  

CONCLUSION: 

  • Non-hospitalized patients with COVID-19 and risk factors for disease progression who received a 3-day course of remdesivir were 87% less likely to require hospitalization or die compared to patients who received placebo 
  • Remdesivir had an acceptable safety profile in this population with incidence of adverse events similar to placebo  
  • The authors state 

In the campaign toward ending the Covid-19 pandemic, these data add yet another option to the armamentarium for the treatment of vulnerable patients who are at high risk for progression to severe Covid-19 

Learn More – Primary Sources: 

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients 

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

RCT Results: Does Remdesivir Improve Clinical Status in Patients with Moderate COVID-19?
The Final Report from ACTT-1 RCT: Remdesivir Decreases Time to Recovery
Remdesivir RCT Results: 5 or 10 Day Treatment for Severe COVID-19?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site